Literature DB >> 7962319

Serum dehydroepiandrosterone sulfate levels as an individual marker.

G Thomas1, N Frenoy, S Legrain, R Sebag-Lanoe, E E Baulieu, B Debuire.   

Abstract

To assess the significance of the serum dehydroepiandrosterone sulfate (DHEAS) concentration as a parameter of the individual hormonal milieu, two different groups of subjects were studied: DHEAS levels were determined 3 times at 6-month intervals in 47 elderly hospitalized women, aged 71-94 yr (group 1), and 6 times over 2 consecutive weeks in 10 healthy male volunteers, aged 24-30 yr (group 2). For reference, serum cortisol (F) levels were determined concomitantly. In each group and on each sampling occasion, the subjects were ranked according to their DHEAS or F values. The stability over time of the ranking was much higher for DHEAS than for F; estimated concordance coefficients were 92% (group 1) and 88% (group 2) for DHEAS vs. 51% (group 1) and 49% (group 2) for F. We conclude that due to a comparatively low within- to between-subject variability ratio, DHEAS is a highly specific individual marker.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962319     DOI: 10.1210/jcem.79.5.7962319

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Dehydroepiandrosterone sulfate and longevity: new clues for an old friend.

Authors:  S S Yen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

Review 2.  Biomarkers related to aging in human populations.

Authors:  Eileen Crimmins; Sarinnapha Vasunilashorn; Jung Ki Kim; Dawn Alley
Journal:  Adv Clin Chem       Date:  2008       Impact factor: 5.394

3.  The short-term effect of dietary pectin on plasma levels and renal excretion of dehydroepiandrosterone sulfate.

Authors:  T Remer; K Pietrzik; F Manz
Journal:  Z Ernahrungswiss       Date:  1996-03

4.  DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE).

Authors:  Chrisandra Shufelt; Philip Bretsky; Cristina M Almeida; B Delia Johnson; Leslee J Shaw; Ricardo Azziz; Glenn D Braunstein; Carl J Pepine; Vera Bittner; Diane A Vido; Frank Z Stanczyk; C Noel Bairey Merz
Journal:  J Clin Endocrinol Metab       Date:  2010-08-25       Impact factor: 5.958

5.  DHEAS levels and mortality in disabled older women: the Women's Health and Aging Study I.

Authors:  Anne R Cappola; Qian-Li Xue; Jeremy D Walston; Sean X Leng; Luigi Ferrucci; Jack Guralnik; Linda P Fried
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-09       Impact factor: 6.053

6.  The association between dehydroepiandosterone and frailty in older men and women.

Authors:  M Voznesensky; S Walsh; D Dauser; J Brindisi; A M Kenny
Journal:  Age Ageing       Date:  2009-03-09       Impact factor: 10.668

Review 7.  Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects.

Authors:  Sylvie Legrain; Laurence Girard
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Trajectories of dehydroepiandrosterone sulfate predict mortality in older adults: the cardiovascular health study.

Authors:  Anne R Cappola; Ellen S O'Meara; Wensheng Guo; Traci M Bartz; Linda P Fried; Anne B Newman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-08-27       Impact factor: 6.053

9.  Dehydroepiandrosterone administration reverses the inhibitory influence of aging on gonadotrophin-releasing hormone gene expression in the male and female rat brain.

Authors:  S Li; L Givalois; G Pelletier
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

10.  Association of serum dehydroepiandrosterone sulfate and cognition in older adults: sex steroid, inflammatory, and metabolic mechanisms.

Authors:  Kerry L Hildreth; Wendolyn S Gozansky; Catherine M Jankowski; Jim Grigsby; Pamela Wolfe; Wendy M Kohrt
Journal:  Neuropsychology       Date:  2013-05       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.